Attenuation of colon carcinoma tumor spread by intravenous immunoglobulin

Maya Damianovich, Arieh Sorin Solomon, Miri Blank, Yehuda Shoenfeld*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

The impact of IVIg on metastatic capacity of CT26 murine colon carcinoma cellswas studied using in vitro and in vivo methods. IVIg inhibited CT26 cell proliferation and invasion through an extracellular matrix in a dose- and time-dependent manner. Systemic treatment of mice with IVIg significantly inhibited metastatic potential of CT26 colon carcinoma cells observed as tumor nodules and lung weight reduction. Treating CT26 cell-implanted rabbit corneas with IVIg led to shrinking and complete disappearance of tumor mass in 10 days. These results provide the evidence that IVIg may be considered as a supportive therapy for inhibition of colon carcinoma tumor spread.

Original languageEnglish
Title of host publicationAutoimmunity, Part B Novel Applications of Basic Research
PublisherBlackwell Publishing Inc.
Pages567-577
Number of pages11
ISBN (Print)1573317098, 9781573317092
DOIs
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1110
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Keywords

  • IVIg
  • Mechanisms
  • Metastases
  • Murine colon carcinoma

Fingerprint

Dive into the research topics of 'Attenuation of colon carcinoma tumor spread by intravenous immunoglobulin'. Together they form a unique fingerprint.

Cite this